This randomized phase 2 study aimed to assess and compare the toxicity and response rates in patients with unresectable non-small cell lung cancer treated with radiotherapy (1.8 -2 Gray [Gy] daily, five fractions a week, total 63 Gy) or radiotherapy + paclitaxel administered weekly (1.8 Gy daily, five fractions a week, total 59.4 Gy). Twelve patients in the latter arm received 30 mg/m 2 paclitaxel (median six cycles) over a 3-h infusion once weekly. After assessing toxicity, the remaining nine patients received 60 mg/m 2 paclitaxel weekly (median six cycles). Response was evaluated radiologically 1 month after treatment. Grade 3 toxicity was 20% and 38% in the radiotherapy and chemoradiotherapy groups, respectively. Overall survival rates in complete and objective (complete plus partial) responders and progression-free survival rate of the objective responders were significantly better in the chemoradiotherapy arm. We believe that using paclitaxel in concurrent chemoradiotherapy regimens may be effective in patients with unresectable, locoregionally advanced non-small cell lung cancer.
Introduction
In patients with stage III non-small cell lung cancer (NSCLC) the 5-year survival rates range between 5% and 10%. These poor rates reflect the inefficacy of standard treatment with radiation therapy (RT), 1 and a need for new perspectives and more aggressive approaches, including strategies combining chemotherapy and radiation. In a meta-analysis of 52 randomized trials it was shown that cisplatin-based chemotherapy resulted in a reduction in the risk of death and an absolute improvement in survival of 10% at 1 year. 2 In addition to direct anti-tumour effects, some chemotherapeutic agents potentiate the effects of radiation. A randomized trial of concurrent cisplatin-based chemoradiotherapy (RT+P) versus radiation alone carried *This study was presented in part at the 21st Annual Meeting of ESTRO, Prague, 2002.
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out by the European Organization for the Research and Treatment of Cancer revealed a survival advantage for the combined treatment. 3 Studies with such positive results have stimulated the search for other radiation-sensitizing agents that could improve survival.
Paclitaxel appears to potentiate the effect of ionizing radiation. 4 Pre-clinical studies have shown that non-cytotoxic doses of paclitaxel, when given concomitantly with radiation, are able to arrest lung cancer cells in the G2/M stages of the cell cycle (the most radiosensitive stages of the cell cycle) with resultant radiation sensitization. 4 -6 Phase 1 studies have indicated that paclitaxel in doses of 60 mg/m 2 over 3 h can be given weekly during RT in NSCLC. 5, 6 Phase 1/2 trials evaluating concurrent administration of paclitaxel with RT in patients with locally advanced NSCLC have shown that this combination is highly active. Overall response rates range from 65% to 86%, and the drug is generally well tolerated. 6, 7 In light of these findings we undertook a prospective randomized phase 2 trial. We aimed to assess the toxicity and response rates to RT with concurrent paclitaxel administered weekly and compare this with RT alone in patients with NSCLC.
Patients and methods

PATIENTS
Patients attending the Department of Radiation Oncology of Uludag University Medical College (Bursa, Turkey) who fulfilled the eligibility criteria for the study were enrolled. In all patients the diagnosis of NSCLC was confirmed by bronchial and/ or transthoracic biopsy and/or sputum cytology. Pre-treatment evaluation included medical history, clinical examination, chest X-rays, pulmonary function tests, a complete blood count, urinanalysis, biochemical survey, chest computed tomography (CT) scan, bone scintigraphy and abdominal CT scan or ultrasonography. All candidates were staged according to the clinical staging classification (American Joint Committee on Cancer, 1997 version). 8 After staging, patients who met the eligibility criteria were randomized (using a table of random numbers) to either the RT arm or RT+P arm. The eligibility criteria were: unresectable, histologically confirmed NSCLC; age > 18 years; Karnofsky performance status ≥ 70%; no prior chemotherapy or RT; adequate haematological, hepatic, pulmonary and renal functions.
Informed consent was obtained from each patient and the study was conducted in accordance with our institutional guidelines.
TREATMENT PROTOCOL
Radiotherapy
Radiotherapy was administered at a daily dose of 1.8 Gray (Gy), five fractions a week up to a total of 63 Gy in the RT arm and 1.8 Gy daily, five fractions a week up to a total of 59.4 Gy in the RT+P arm. The dosage of 63 Gy for the RT arm was based on data from our previous phase 2 study. 9 Briefly, after simulation, target volume and normal organs were localized on CT slices. The dose was prescribed at the 90% isodose distribution of the proposed target volume. We routinely use CT planning to correct for lung inhomogeneities.
Treatment was carried out using a linear accelerator with energies of 6 -25 MV. The patient lay supine with their arms over their head. RT was given through anteroposteriorposteroanterior portals with a median of 45 Gy in 25 fractions delivered to the original volume with a 2 cm margin around any gross tumour seen on CT scan and approximately a 1 cm margin around electively treated regional lymph node areas. The boost volume was defined as the primary tumour Radiotherapy versus radiotherapy + paclitaxel in NSCLC site and involved lymph nodes with additional 1 cm margin excluding the spinal cord and other normal tissues as much as possible.
Chemotherapy
Patients were pre-medicated with dexamethasone (16 mg), ranitidine (50 mg), diphenhydramine (40 mg), granisetron (3 mg) or ondansetron (4 mg) intravenously in 250 ml normal saline, 30 min prior to the paclitaxel infusion. Paclitaxel was diluted in 500 ml 5% dextrose injection and administered as a continuous intravenous infusion over 3 h. This method of infusion was selected on the basis of experience gained from clinical studies and in vitro data on tolerability and effectiveness. 5, 7 Vital signs were monitored during the infusion, and medications for anaphylaxis were available at the bedside. The starting infusion time was approximately 1 h before radiation.
The first 12 patients received 30 mg/m 2 paclitaxel over the 3-h infusion period once weekly. After assessing the toxicity and safety of the treatment, 60 mg/m 2 paclitaxel weekly was given to the remaining nine patients using the administration schedule already described. Patients were seen weekly during the study for complete blood cell counts and evaluation of toxicity. Additional therapy was given to patients with progressive disease. Toxicity was evaluated according to the Radiation Therapy Oncology Group (RTOG) and World Health Organization toxicity criteria. Toxicity was judged as acute if it occurred during treatment or within the first month after completing therapy.
EVALUATION OF TREATMENT RESPONSE
The response to treatment was evaluated 1 month after completing the therapy using a thorax CT scan following standardized criteria. Complete response was defined as regression of all detectable disease and absence of a new lesion, and partial response as decrease of at least 50% of tumour volume and the absence of a new lesion. Objective response was defined as complete plus partial response. Stable disease was detected if the evaluation failed to qualify for any of the responses noted earlier, and progressive disease occurred if an increase of at least 25% in the size of one or more measurable lesions or any new lesions was seen.
FOLLOW-UP
Patients were routinely seen for follow-up 1 month after the completion of treatment, and then every 3 months for the first 2 years. At follow-up, a physical examination, chest X-ray, and haematological and biochemical blood tests were carried out. Survival time was defined as the time from randomization until death or last-known follow-up. Progression-free survival was calculated as the time between randomization and disease progression.
STATISTICAL ANALYSIS
The survival distribution was calculated by the Kaplan-Meier method, and the log-rank test was used for between-group comparisons. A P-value < 0.05 was considered statistically significant. Table 1 .
Results
Toxicity was evaluated in all patients ( Table 2 ). Grade 4 toxicity was not observed. The overall grade 3 toxicity rate was 20% (4/20) and 38% (8/21) for the RT and RT+P groups, respectively. Grade 3 oesophagitis was only seen in one patient in the RT+P arm. In all other patients with oesophagitis, it was grade 1 or 2 and was managed with oral therapy. All patients but two developed skin reactions during radiation therapy. Grades 1, 2 and 3 skin reactions were noted in 20, 14 and five patients, respectively. Grades 1 and 2 lung toxicities were observed in two patients treated with RT+P and grade 1 lung toxicity was observed in six patients treated with RT. Radiation pneumonitis (grade 3 lung toxicity) was seen in six patients within a median of 4 weeks (range, 2 -8) after the completion of treatment. Haematotoxicity was similar in the RT and RT+P arms. The differences between the 30 mg/m 2 and 60 mg/m 2 paclitaxel schedules in the rates of response and toxicity were non-significant. No diarrhoea, nausea, vomiting or neurological toxicity was observed. No patients required hospitalization for toxicity and there were no fatal complications during the follow-up period.
Response was evaluated radiologically 1 month after the completion of treatment ( Table 3 ). The median duration of response was 6 months (range, 1 -19), and the 1-year progression-free survival was 32%.
The overall median survival time was 16 months (range, 2 -74): 10 months (range, 2 -55) in the RT arm and 17 months (range, 6 -74) in the RT+P arm. The difference between the two groups did not reach statistical significance. Overall survival rates in complete and objective responders were significantly better in the RT+P arm (P = 0.055 and P = 0.0000, respectively, see Figs 1 and 2). No significant differences for survival were observed with regard to stage, histological subtype or S Sarihan, U Kayisogullari, I Ercan et al.
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paclitaxel dose (30 mg/m 2 and 60 mg/m 2 ). A slight increase in overall survival was observed in older patients (≥ 58 years; P = 0.098).
Overall median progression-free survival was 8 months (range, 1 -73): 6 months (range, 1 -49) in the RT arm and 9 months (range, 1 -73) in the RT+P arm, the difference not reaching statistical significance. Progression-free survival rates of objective responders were significantly better in the RT+P arm (P = 0.0014; Fig. 3 ). No significant differences in progression-free survival rates were observed with regard to complete response, age, stage, histological subtype or paclitaxel dose.
Treatment compliance appeared to be good in both treatment arms. In the RT arm, three patients received one or two fewer fractions due to infection and grade 1 lung toxicity. Four patients received an additional one or two fractions because of interruption due to machine breakdown or holidays. One patient received a total of 64 Gy with 2 Gy daily fractions. All patients in the RT+P arm completed treatment except for one who received 54 Gy due to grade 2 lung toxicity. After determining the feasibility of 30 mg/m 2 paclitaxel in the first 12 patients (median six cycles; range, 5 -7), 60 mg/m 2 paclitaxel was given to the remaining nine patients for six cycles (range, 6 -7). A total of 15 patients had recurrence of tumour at a median of 8 months (range, 3 -21) in the two groups. Seven were seen in the RT arm and eight in the RT+P arm ( Table 4 ). The most frequent sites of metastases were bone (n = 11), brain (n = 4), liver (n = 3), lung (n = 2) and adrenal gland (n = 1). Patients with progressive disease were treated with chemotherapy and/or palliative RT. 
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Discussion
Radiation therapy is the standard local therapy for patients with unresectable locally advanced NSCLC. 1 The median survival for such patients is 9 -11 months with conventional fractionation. Survival has improved with the addition of some chemotherapeutic agents that enhance the effects of thoracic RT. 2, 3 Paclitaxel is a potent microtubule stabilizing agent that selectively blocks cells in the G2 and M stages of the cell cycle. 4 The weekly dosing interval is well tolerated and results in less myelotoxicity and neuropathy than conventional 21-day schedules. 5, 6 A weekly 3-h infusion schedule provides continuous radiosensitizing plasma drug levels and is tolerable and adaptable to the out-patient setting.
Choy et al. 10 administered radiation therapy up to a total of 60 Gy using a fractionation of 5 × 2 Gy per week and concurrent paclitaxel once weekly over 5 or 6 weeks. Dose escalation studies and various phase 1/2 trials using concurrent paclitaxel and thoracic irradiation for NSCLC patients have shown that the optimal paclitaxel dose is 60 mg/m 2 per week. 5 -7,11 In our phase 2 study patients received a fractionation of 5 × 1.8 Gy per week up to a total median dose of 59.4 Gy using the shrinking-field technique over 6.5 weeks. We also used the 60 mg/m 2 weekly paclitaxel dose in light of previous studies.
The incidence of grade 3 or worse oesophagitis has been reported to be 1.2% in patients treated with 60 Gy in 30 fractions. It is known that the combination of radiation and chemotherapy may significantly increase the incidence of oesophagitis. Oesophagitis was seen in 5% of patients treated with RT alone and 5 -53% of patients treated with combined RT+P in various studies. 12 In the three phase 2 trials, oesophagitis was the main toxicity ranging from 17% to 26% using the RTOG criteria. 12 Rates of grade ≥ 3 oesophagitis with combined paclitaxel and irradiation of 60 Gy over 6 weeks in NSCLC were reported to be between 14% and 37%. 6, 10 Vogt et al. 7 reported 4% (1/24) grade 3 oesophagitis with paclitaxel and thoracic irradiation with a dose of 59.4 Gy. We had only one patient with severe (grade 3) oesophagitis in the RT+P arm. This may be because of the lower daily dose of 1.8 Gy that we and some other investigators used.
Radiation pneumonitis (both symptomatic and radiographical) has been reported in 5 -15% of patients in the literature. 1 Choy et al. 10 reported that one patient developed Copyright © 2004 Cambridge Medical Publications radiation pneumonitis (4%) in the study of combined paclitaxel and irradiation in NSCLC. In our study, the occurrence of radiation pneumonitis was similar (at median 4 weeks after therapy) in both the RT and RT+P arms (15%, 3/20 and 14%, 3/21, respectively). An overall acute toxicity rate of 33% was observed with combined treatment.
We also assessed the effect of this combined regimen on tumour control and survival. Overall response rates of 74 -86% and 7 -17% complete response rates with weekly paclitaxel and conventional thoracic RT in NSCLC have been reported. 6, 10, 11 We obtained an objective response rate of 86% (18/21) and complete radiological response rate of 19% (4/21) in the RT+P arm. The responses were seen in patients with radiological stages IIB, IIIA and IIIB. The median duration of response was 6 months (range, 1 -19), and the overall 1-year disease-free survival was 32%.
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Since there were no significant differences in patient characteristics between the two treatment arms, the difference in survival can be attributed to the difference in treatment. Akerley and Choy 6 reported a median survival of 20 months and 1-, 2-and 3-year survival rates of 61%, 33% and 18%, respectively. Our median duration of survival was 17 months (range, 6 -74) and 1-and 2-year survival rates were 64% and 26%, respectively, in the RT+P arm. Overall survival rates of complete and objective responders were significantly better in the RT+P arm (P = 0.055 and P = 0.0000, respectively). Progression-free survival rate of objective responders was also significantly better in the RT+P arm (P = 0.0014).
These results demonstrate the feasibility and potential efficacy of paclitaxel administered concurrently with thoracic irradiation for treating locoregionally advanced, inoperable NSCLC.
